^
Association details:
| Biomarker: | MGMT promoter methylation |
|---|---|
| Cancer: | Glioma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + ProstAtak (aglatimagene besadenovec) (Gene transference, Thymidine kinase stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
Published date:
11/08/2022
Excerpt:
Median OS (mOS) for patients with methylated MGMT promoter was 30.6mo for patients undergoing gross total resection (GTR) and 12.6mo for patients undergoing sub-total resection (STR)....Combination treatment of CAN-2409/valacyclovir plus nivolumab and SoC induces profound immunological changes and appears to associate with encouraging survival data.
Secondary therapy:
valacyclovir
DOI:
http://dx.doi.org/10.1136/jitc-2022-SITC2022.1477
Trial ID:
